{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:47:05Z","timestamp":1794952025382,"version":"4.9.1"},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":4174,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1997,2]]},"abstract":"<jats:p> <jats:italic>Aim<\/jats:italic>: To test the hypothesis that 1\u2010week low\u2010dose triple therapy for <jats:italic>H. pylori<\/jats:italic> is sufficient for relief from dyspeptic symptoms and healing of duodenal ulcers.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>: Fifty\u2010nine out\u2010patients with duodenal ulcers and positive rapid urease test participated in this randomized, double\u2010blind, two\u2010centre study. All patients were treated for 1 week with omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and metronidazole 400 mg b.d. In a double\u2010blind fashion, patients were then randomly treated for another 3 weeks with either omeprazole 20 mg once daily or an identical\u2010looking placebo. Patients were investigated endoscopically before treatment for <jats:italic>H. pylori<\/jats:italic>, after 2 weeks and after 4 weeks. <jats:italic>H. pylori<\/jats:italic> infection was assessed by a <jats:sup>13<\/jats:sup>C\u2010urea breath test at the time of enrolment and 4 weeks after cessation of any study medication.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>: Fifty\u2010two patients were included in the \u2018all patients treated\u2019 analysis of efficacy. The overall <jats:italic>H. pylori<\/jats:italic> cure rate was 96% (95% CI=87\u2013100%), with no difference between the treatment groups. After 2 weeks duodenal ulcer healing was confirmed in 91% (95% CI=80\u2013100%) of patients treated with omeprazole and in 76% (95% CI=60\u201391%) in the placebo group (<jats:italic>P<\/jats:italic>=0.14). After 4 weeks all ulcers had healed. Relief from dyspeptic symptoms and adverse events (13.8 and 16.7%) did not differ between the treatment groups.<\/jats:p><jats:p> <jats:italic>Conclusions<\/jats:italic>: One\u2010week low\u2010dose triple therapy consisting of omeprazole, clarithromycin and metronidazole is a highly effective and well\u2010tolerated approach to the cure of <jats:italic>H. pylori<\/jats:italic> infection in patients with a duodenal ulcer. Our data suggest that continuation of antisecretory drug therapy beyond anti\u2010<jats:italic>H. pylori<\/jats:italic> therapy is actually excessive regarding relief from dyspeptic symptoms and healing of duodenal ulcers.<\/jats:p>","DOI":"10.1046\/j.1365-2036.1997.80252000.x","type":"journal-article","created":{"date-parts":[[2003,10,15]],"date-time":"2003-10-15T03:18:39Z","timestamp":1066187919000},"page":"89-93","source":"Crossref","is-referenced-by-count":43,"title":["One\u2010week low\u2010dose triple therapy for <i>Helicobacter pylori<\/i> is sufficient for relief from symptoms and healing of duodenal ulcers"],"prefix":"10.1111","volume":"11","author":[{"given":"J.","family":"LABENZ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010P.","family":"IDSTR\u00d6M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"TILLENBURG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"PEITZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"ADAMEK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"B\u00d6RSCH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1997.80252000.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1997.80252000.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:19:35Z","timestamp":1694395175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1997.80252000.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,2]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,2]]}},"alternative-id":["10.1046\/j.1365-2036.1997.80252000.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1997.80252000.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,2]]}}}